GvHD: A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment
of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
Will taking ruxolitinib in combination with corticosteroids be a safe and effective
treatment for people with acute Graft vs Host Disease (GvHD)?
Basic Study Information
Purpose:Location: Cancer Center
This is an open-label Study which means that both you and your Study Doctor will know
what Study Drug you are receiving. Eligible subjects will begin treatment at 5 mg
ruxolitinib twice daily. This may be increased to 10 mg twice daily after 3 days depending
on your blood tests.
Study Web URL: https://clinicaltrials.gov/ct2/show/NCT02953678?term=INCB+18424-271&rank=1
Study Reference #: IBMT-17007
Lead Researcher (Principal Investigator)
Lead Researcher: Jane Liesveld, MD
Study Contact InformationStudy Coordinator: Katherine Nedrow
Phone: (585) 275-9485
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search